Considering the data pointing to a pathological role of MPO in promoting plaque instability and post-MI cardiac complications, studies investigating whether pharmacological MPO inhibition can also attenuate the risk of CAD and ACS patients or improve cardiovascular remodelling and dysfunction in MI survivors are warranted. Here, MPO is linked to coronary artery disorder.